中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2014年
9期
932-935
,共4页
喜炎平%慢性阻塞性肺疾病%急性加重期%炎症因子%肺功能
喜炎平%慢性阻塞性肺疾病%急性加重期%炎癥因子%肺功能
희염평%만성조새성폐질병%급성가중기%염증인자%폐공능
Xiyanping injections%Chronic obstructive pulmonary disease%Acute exacerbation%Inflammation factors%Lung function
目的 观察喜炎平对老年慢性阻塞性肺疾病急性加重期(AECOPD)患者炎症因子和肺功能的影响.方法 92例老年AECOPD患者按照随机数字表分为对照组46例和观察组46例.对照组给予常规治疗,观察组在对照组治疗基础上加用喜炎平注射液,疗程2周.比较治疗前后两组C反应蛋白(CRP)、红细胞沉降率(ESR)、白细胞介素10(IL-10)、第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC变化以及临床效果.结果 两组治疗前CRP、ESR及IL-10差异无统计学意义(P均＞0.05);治疗后两组CRP及ESR均较前明显下降[对照组:CRP(35.6±9.8)mg/L降为(14.2 ±8.1)mg/L(t=-14.515,P＜0.05),ESR(56.2±16.4) mm/1 h降为(22.4±11.6) mm/1 h(t=-12.008,P＜0.05);观察组:CRP(36.4±8.2) mg/L降为(8.2±6.2) mg/L(t=-18.468,P＜0.05),ESR(54.6±15.4)mm/1 h降为(16.8±9.6)mm/1 h(t=-15.249,P＜0.05)],且观察组下降更为明显.而治疗后IL-10呈上升趋势[对照组(168.8±62.4)ng/L升为(212.4±85.6) ng/L(t =5.468,P＜0.05),观察组(172.8±65.1)ng/L升为(266.4±92.6)ng/L(t=6.368,P＜0.05)],观察组上升更为明显.治疗后两组FEV1及FVC均明显上升[对照组:FEV1由(1.41 ±0.15)L升为(1.62±0.18) L(t =2.186,P＜0.05),FVC(2.62±0.88)L升为(2.89±0.92)L(=2.415,P＜0.05);观察组:FEV1 (1.42±0.16)L升为(1.84±0.21) L(t =4.366,P＜0.05),FVC(2.59±0.84)L升为(3.12±0.94) L(t =4.585,P＜0.05)].观察组总有效率91.3％ (42/46)明显高于对照组78.3％ (36/46),差异有统计学意义(x2=4.658,P＜0.05).结论 喜炎平可以减轻AECOPD患者的炎症反应,改善肺功能,提高治疗效果.
目的 觀察喜炎平對老年慢性阻塞性肺疾病急性加重期(AECOPD)患者炎癥因子和肺功能的影響.方法 92例老年AECOPD患者按照隨機數字錶分為對照組46例和觀察組46例.對照組給予常規治療,觀察組在對照組治療基礎上加用喜炎平註射液,療程2週.比較治療前後兩組C反應蛋白(CRP)、紅細胞沉降率(ESR)、白細胞介素10(IL-10)、第1秒用力呼氣容積(FEV1)、用力肺活量(FVC)、FEV1/FVC變化以及臨床效果.結果 兩組治療前CRP、ESR及IL-10差異無統計學意義(P均＞0.05);治療後兩組CRP及ESR均較前明顯下降[對照組:CRP(35.6±9.8)mg/L降為(14.2 ±8.1)mg/L(t=-14.515,P＜0.05),ESR(56.2±16.4) mm/1 h降為(22.4±11.6) mm/1 h(t=-12.008,P＜0.05);觀察組:CRP(36.4±8.2) mg/L降為(8.2±6.2) mg/L(t=-18.468,P＜0.05),ESR(54.6±15.4)mm/1 h降為(16.8±9.6)mm/1 h(t=-15.249,P＜0.05)],且觀察組下降更為明顯.而治療後IL-10呈上升趨勢[對照組(168.8±62.4)ng/L升為(212.4±85.6) ng/L(t =5.468,P＜0.05),觀察組(172.8±65.1)ng/L升為(266.4±92.6)ng/L(t=6.368,P＜0.05)],觀察組上升更為明顯.治療後兩組FEV1及FVC均明顯上升[對照組:FEV1由(1.41 ±0.15)L升為(1.62±0.18) L(t =2.186,P＜0.05),FVC(2.62±0.88)L升為(2.89±0.92)L(=2.415,P＜0.05);觀察組:FEV1 (1.42±0.16)L升為(1.84±0.21) L(t =4.366,P＜0.05),FVC(2.59±0.84)L升為(3.12±0.94) L(t =4.585,P＜0.05)].觀察組總有效率91.3％ (42/46)明顯高于對照組78.3％ (36/46),差異有統計學意義(x2=4.658,P＜0.05).結論 喜炎平可以減輕AECOPD患者的炎癥反應,改善肺功能,提高治療效果.
목적 관찰희염평대노년만성조새성폐질병급성가중기(AECOPD)환자염증인자화폐공능적영향.방법 92례노년AECOPD환자안조수궤수자표분위대조조46례화관찰조46례.대조조급여상규치료,관찰조재대조조치료기출상가용희염평주사액,료정2주.비교치료전후량조C반응단백(CRP)、홍세포침강솔(ESR)、백세포개소10(IL-10)、제1초용력호기용적(FEV1)、용력폐활량(FVC)、FEV1/FVC변화이급림상효과.결과 량조치료전CRP、ESR급IL-10차이무통계학의의(P균＞0.05);치료후량조CRP급ESR균교전명현하강[대조조:CRP(35.6±9.8)mg/L강위(14.2 ±8.1)mg/L(t=-14.515,P＜0.05),ESR(56.2±16.4) mm/1 h강위(22.4±11.6) mm/1 h(t=-12.008,P＜0.05);관찰조:CRP(36.4±8.2) mg/L강위(8.2±6.2) mg/L(t=-18.468,P＜0.05),ESR(54.6±15.4)mm/1 h강위(16.8±9.6)mm/1 h(t=-15.249,P＜0.05)],차관찰조하강경위명현.이치료후IL-10정상승추세[대조조(168.8±62.4)ng/L승위(212.4±85.6) ng/L(t =5.468,P＜0.05),관찰조(172.8±65.1)ng/L승위(266.4±92.6)ng/L(t=6.368,P＜0.05)],관찰조상승경위명현.치료후량조FEV1급FVC균명현상승[대조조:FEV1유(1.41 ±0.15)L승위(1.62±0.18) L(t =2.186,P＜0.05),FVC(2.62±0.88)L승위(2.89±0.92)L(=2.415,P＜0.05);관찰조:FEV1 (1.42±0.16)L승위(1.84±0.21) L(t =4.366,P＜0.05),FVC(2.59±0.84)L승위(3.12±0.94) L(t =4.585,P＜0.05)].관찰조총유효솔91.3％ (42/46)명현고우대조조78.3％ (36/46),차이유통계학의의(x2=4.658,P＜0.05).결론 희염평가이감경AECOPD환자적염증반응,개선폐공능,제고치료효과.
Objective To investigate the influence of Xiyanping injections therapy on inflammation factors and lung function for old patients with acute exacerbation chronic obstructive pulmonary disease (AECOPD).Methods Ninety-two patients with AECOPD were randomly divided into the control group (n =46) and observation group(n =46).Patients in control group were given conventional treatment,in observation group were given XiYanPing injections for 2 weeks treatment on the basis of treatment of control group.The C-reactive protein(CRP),blood sedimentation rate (ESR),interleukin 10 (IL-10),1 s forced expiratory volume (FEV1),forced vital capacity (FVC),FEV1/FVC change and clinical effect of the two groups were recorded.Results There was no statistically significant difference in terms of CRP,ESR and IL-10 between the two groups before treatment (P ＞ 0.05).After treatment,CRP and ESR in control group were reduced from (35.6 ±9.8) mg/L and (56.2 ± 16.4) mm/h to (14.2 ± 8.1) mg/L and (22.4 ± 11.6) mm/1 h and the difference was significant (t =-14.515,-12.008;P ＜ 0.05),while in observation group decreased from (36.4 ± 8.2) mg/L,(54.6 ± 15.4) to (8.2 ± 6.2) mg/L,(16.8 ± 9.6) mm/h and the difference was significant (t =-18.468,-15.249;P ＜ 0.05).Meanwhile,the level of IL-10 in the two groups significantly increased and the observation group showed more.IL-10 in control group increased from (168.8 ± 62.4) ng/L to (212.4 ± 85.6) ng/L and the difference was significant(t =5.468,P ＜ 0.05),and in observation group increased from (172.8 ± 65.1) ng/L to (266.4 ± 92.6) ng/L and the difference was significant (t =6.368,P ＜ 0.05).The FEV1 and FVC were markedly increased after treatment and the observation group showed increase more.FEV1and FVC in control group were increased from (1.41 ±0.15) L and (2.62 ±0.88) L to (1.62 ± 0.18) L and (2.89 ± 0.92) L,and the differences were significant (t =2.186,2.415 ; P ＜ 0.05).While in observation group,FEV1 and FVC were increased from (1.42 ± 0.16) L and (2.59 ± 0.84) L to (1.84 ±0.21) L and (3.12 ± 0.94) L,and the differences were significant (t =4.366,4.585 ; P ＜ 0.05).Total efficacy of observation group was 91.3％ (42/46),obviously higher than that of control group(78.3％ (36/46) ; x2 =4.658 ;P ＜ 0.05).Conclusion Xiyanping injections can reduce the inflammatory response in patients with AECOPD,improve lung function and the effect of treatment.
